No Data
No Data
Kronos Bio to Present Data at ACR Convergence 2024 to Support P300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
The Top Five Long Crowded Stocks in Each U.S. Sector
Kronos Bio Highlights Preclinical Data At AACR Symposium Supporting Istisociclib Clinical Evaluation In Advanced Ovarian Cancer, Showing Efficacy In Platinum And PARP-Inhibitor Resistant Models
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium That Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Kronos Bio Announces Participation in Medical and Investor Conferences in September